Ovary, Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
Volunteers
Health Professionals
What is the purpose of this trial?
Primary Objectives:
- To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function.
- To assess the safety and tolerability of lademirsen (SAR339375) in participants with Alport syndrome.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan
- Blair Colette McNamara, MD
- Clarice Grens
- Elena Ratner, MD, MBA
- Gary Altwerger, MD
- Jamie Malette
- Justin Persico, MD
- Kathleen Fenn, MD
- Katyayani (Katya) Papatla, MD/MPH
- Lisa Baker
- Martha Diaz
- Masoud Azodi, MD
- Megin Iaccarino
- Michelle Greenman
- Nesrine Khoury
- Peter Dottino, MD, FACOG
- Rebecca Bartomeli
- Renee Moye
- Last Updated12/10/2024
- Study HIC#2000036114